Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 4 boards, counting each seat separately. Longest: Atara Biotherapeutics Inc., 3 years.
Atara Biotherapeutics Inc.
Director
Ultragenyx Pharmaceutical Inc.
Director
Neumora Therapeutics Inc.
Director
Electra Therapeutics Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Neumora Therapeutics Inc. May 27, 202694.4%
-
Atara Biotherapeutics Inc. June 10, 202584.9%
-
Ultragenyx Pharmaceutical Inc. May 15, 202586.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 9, 2026 | Atara Biotherapeutics Inc. | Grant or award | +12,000 | — | — |
| May 14, 2026 | Ultragenyx Pharmaceutical Inc. | Grant or award | +7,751 | — | — |
| Jun 10, 2025 | Atara Biotherapeutics Inc. | Grant or award | +7,828 | — | — |
| May 15, 2025 | Ultragenyx Pharmaceutical Inc. | Grant or award | +5,740 | — | — |
| Oct 18, 2024 | Neumora Therapeutics Inc. | Option exercise | +6,205 | $8.79 | $54,542 |
| Oct 18, 2024 | Neumora Therapeutics Inc. | Option exercise | +7,844 | $2.52 | $19,767 |
| Oct 18, 2024 | Neumora Therapeutics Inc. | Open-market sale | −14,049 | $17.03 | $239,254 |
| Oct 17, 2024 | Neumora Therapeutics Inc. | Option exercise | +3,783 | $8.32 | $31,475 |
| Oct 17, 2024 | Neumora Therapeutics Inc. | Option exercise | +1,800 | $8.79 | $15,822 |
| Oct 17, 2024 | Neumora Therapeutics Inc. | Option exercise | +2,156 | $2.52 | $5,433 |
| Oct 17, 2024 | Neumora Therapeutics Inc. | Open-market sale | −7,739 | $17.01 | $131,640 |
| Jun 18, 2024 | Ultragenyx Pharmaceutical Inc. | Grant or award | +5,345 | — | — |
| Jun 13, 2024 | Neumora Therapeutics Inc. | Grant or award | +20,100 | — | — |
| Mar 31, 2024 | Atara Biotherapeutics Inc. | Grant or award | +150,000 | — | — |
| Mar 7, 2024 | Ultragenyx Pharmaceutical Inc. | Open-market sale | −2,550 | $50.89 | $129,770 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.